Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 339

1.

Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.

van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HSA, Rutgers EJ, Russell NS, Smit VTHBM, Voogd AC, Koppert LB, Siesling S, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar RAEM.

Ann Surg. 2018 May 1. doi: 10.1097/SLA.0000000000002804. [Epub ahead of print]

PMID:
29727326
2.

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, Bierman C, van Leeuwen FE, Rutgers EJ, Schmidt MK, Lips EH, Wesseling J.

Clin Cancer Res. 2018 Apr 23. doi: 10.1158/1078-0432.CCR-18-0201. [Epub ahead of print]

PMID:
29685879
3.

Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®)" [Eur J Cancer 75 (April 2017) 5-13].

Makama M, Drukker CA, Rutgers EJT, Slaets L, Cardoso F, Rookus MA, Tryfonidis K, Van't Veer LJ, Schmidt MK.

Eur J Cancer. 2018 Jun;96:131-132. doi: 10.1016/j.ejca.2018.03.017. Epub 2018 Apr 12. No abstract available.

PMID:
29656866
4.

Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL and TEAM Study Groups.

Eur J Cancer. 2018 May;95:59-67. doi: 10.1016/j.ejca.2018.03.014. Epub 2018 Apr 7.

PMID:
29635145
5.

Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Rutgers EJT, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Pilar Zamora M, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM.

Nat Commun. 2018 Apr 10;9:16193. doi: 10.1038/ncomms16193.

6.

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL Study Group.

Breast Cancer Res Treat. 2018 Apr;168(2):413-420. doi: 10.1007/s10549-017-4601-1. Epub 2017 Dec 12.

7.

Association analysis identifies 65 new breast cancer risk loci.

Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, Kristensen VN, Krüger U, Kwong A, Lambrechts D, Le Marchand L, Lee E, Lee MH, Lee JW, Neng Lee C, Lejbkowicz F, Li J, Lilyquist J, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Lophatananon A, Lubinski J, Luccarini C, Lux MP, Ma ESK, MacInnis RJ, Maishman T, Makalic E, Malone KE, Kostovska IM, Mannermaa A, Manoukian S, Manson JE, Margolin S, Mariapun S, Martinez ME, Matsuo K, Mavroudis D, McKay J, McLean C, Meijers-Heijboer H, Meindl A, Menéndez P, Menon U, Meyer J, Miao H, Miller N, Taib NAM, Muir K, Mulligan AM, Mulot C, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Noh DY, Nordestgaard BG, Norman A, Olopade OI, Olson JE, Olsson H, Olswold C, Orr N, Pankratz VS, Park SK, Park-Simon TW, Lloyd R, Perez JIA, Peterlongo P, Peto J, Phillips KA, Pinchev M, Plaseska-Karanfilska D, Prentice R, Presneau N, Prokofyeva D, Pugh E, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Ruddy KJ, Rüdiger T, Rudolph A, Ruebner M, Rutgers EJT, Saloustros E, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Scott RJ, Scott C, Seal S, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng G, Sherman ME, Shrubsole MJ, Shu XO, Smeets A, Sohn C, Southey MC, Spinelli JJ, Stegmaier C, Stewart-Brown S, Stone J, Stram DO, Surowy H, Swerdlow A, Tamimi R, Taylor JA, Tengström M, Teo SH, Beth Terry M, Tessier DC, Thanasitthichai S, Thöne K, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Truong T, Tseng CC, Tsugane S, Ulmer HU, Ursin G, Untch M, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van der Kolk L, van der Luijt RB, Vincent D, Vollenweider J, Waisfisz Q, Wang-Gohrke S, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yamaji T, Yang XR, Har Yip C, Yoo KY, Yu JC, Zheng W, Zheng Y, Zhu B, Ziogas A, Ziv E; ABCTB Investigators; ConFab/AOCS Investigators, Lakhani SR, Antoniou AC, Droit A, Andrulis IL, Amos CI, Couch FJ, Pharoah PDP, Chang-Claude J, Hall P, Hunter DJ, Milne RL, García-Closas M, Schmidt MK, Chanock SJ, Dunning AM, Edwards SL, Bader GD, Chenevix-Trench G, Simard J, Kraft P, Easton DF.

Nature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284. Epub 2017 Oct 23.

8.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

PMID:
29045519
9.

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.

Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litière S, Cardoso F; MINDACT investigators.

Breast Cancer Res Treat. 2018 Jan;167(1):123-131. doi: 10.1007/s10549-017-4509-9. Epub 2017 Sep 19.

PMID:
28929359
10.

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).

Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok AE, Liefers GJ, Nortier JWR, Rutgers EJT, van de Velde CJH; IDEAL Study Group.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx134.

PMID:
28922787
11.

Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.

Schreuder K, Kuijer A, Rutgers EJT, Smorenburg CH, van Dalen T, Siesling S.

Eur J Cancer. 2017 Oct;84:270-277. doi: 10.1016/j.ejca.2017.07.042. Epub 2017 Aug 24.

PMID:
28844015
12.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.

PMID:
28838210
13.

Current approach of the axilla in patients with early-stage breast cancer.

Mamounas EP, Kuehn T, Rutgers EJT, von Minckwitz G.

Lancet. 2017 Aug 14. pii: S0140-6736(17)31451-4. doi: 10.1016/S0140-6736(17)31451-4. [Epub ahead of print] Review.

PMID:
28818521
14.

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

Kuijer A, Straver M, den Dekker B, van Bommel ACM, Elias SG, Smorenburg CH, Wesseling J, Linn SC, Rutgers EJT, Siesling S, van Dalen T.

J Clin Oncol. 2017 Aug 20;35(24):2814-2819. doi: 10.1200/JCO.2016.70.3959. Epub 2017 Mar 13.

PMID:
28813638
15.

Rapid genetic counseling and testing in newly diagnosed breast cancer: Patients' and health professionals' attitudes, experiences, and evaluation of effects on treatment decision making.

Wevers MR, Aaronson NK, Bleiker EMA, Hahn DEE, Brouwer T, van Dalen T, Theunissen EB, van Ooijen B, de Roos MA, Borgstein PJ, Vrouenraets BC, Vriens E, Bouma WH, Rijna H, Vente JP, Kuenen MA, van der Sanden-Melis J, Witkamp AJ, Rutgers EJT, Verhoef S, Ausems MGEM.

J Surg Oncol. 2017 Dec;116(8):1029-1039. doi: 10.1002/jso.24763. Epub 2017 Jul 13.

PMID:
28703900
16.

The intraoperative assessment of sentinel nodes - Standards and controversies.

van der Noordaa MEM, Vrancken Peeters MTFD, Rutgers EJT.

Breast. 2017 Aug;34 Suppl 1:S64-S69. doi: 10.1016/j.breast.2017.06.031. Epub 2017 Jul 1. Review.

17.

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, Rodenhuis S, Valdés Olmos RA, Rutgers EJ, Vogel WV, Sonke GS, Vrancken Peeters MT.

Cancer Imaging. 2017 May 25;17(1):15. doi: 10.1186/s40644-017-0117-5.

18.

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling J, Rutgers EJT, Valdés Olmos RA, Sonke GS, Rodenhuis S, Vrancken Peeters MJTFD, Gilhuijs KGA.

PLoS One. 2017 May 22;12(5):e0176782. doi: 10.1371/journal.pone.0176782. eCollection 2017.

19.

Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.

Koolen BB, Donker M, Straver ME, van der Noordaa MEM, Rutgers EJT, Valdés Olmos RA, Vrancken Peeters MJTFD.

Br J Surg. 2017 Aug;104(9):1188-1196. doi: 10.1002/bjs.10555. Epub 2017 May 19.

PMID:
28524246
20.

Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.

Aalders KC, Kuijer A, Straver ME, Slaets L, Litiere S, Viale G, Van't Veer LJ, Glas AM, Delorenzi M, van Dalen T, Tryfonidis K, Piccart MJ, Cardoso F, Rutgers EJ; TRANSBIG Consortium and the MINDACT Investigators.

Eur J Cancer. 2017 Jul;79:98-105. doi: 10.1016/j.ejca.2017.03.034. Epub 2017 May 3.

PMID:
28477490
21.

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

Engelhardt EG, van den Broek AJ, Linn SC, Wishart GC, Rutgers EJT, van de Velde AO, Smit VTHBM, Voogd AC, Siesling S, Brinkhuis M, Seynaeve C, Westenend PJ, Stiggelbout AM, Tollenaar RAEM, van Leeuwen FE, van 't Veer LJ, Ravdin PM, Pharaoh PDP, Schmidt MK.

Eur J Cancer. 2017 Jun;78:37-44. doi: 10.1016/j.ejca.2017.03.015. Epub 2017 Apr 14.

PMID:
28412587
22.

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

Elshof LE, Schmidt MK, Rutgers EJT, van Leeuwen FE, Wesseling J, Schaapveld M.

Ann Surg. 2018 May;267(5):952-958. doi: 10.1097/SLA.0000000000002239.

23.

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

Elshof LE, Schaapveld M, Rutgers EJ, Schmidt MK, de Munck L, van Leeuwen FE, Wesseling J.

Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.

24.

An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint®).

Makama M, Drukker CA, Rutgers EJT, Slaets L, Cardoso F, Rookus MA, Tryfonidis K, Van't Veer LJ, Schmidt MK.

Eur J Cancer. 2017 Apr;75:5-13. doi: 10.1016/j.ejca.2016.12.024. Epub 2017 Feb 16. Erratum in: Eur J Cancer. 2018 Apr 12;:.

PMID:
28214658
25.

70-Gene Signature in Early-Stage Breast Cancer.

van’t Veer LJ, Rutgers EJT, Piccart M.

N Engl J Med. 2016 Dec 1;375(22):2200-2201. doi: 10.1056/NEJMc1612048. No abstract available.

PMID:
27959762
26.

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J.

Breast Cancer Res Treat. 2017 Jan;161(2):389-390. doi: 10.1007/s10549-016-4060-0. No abstract available.

PMID:
27878644
27.

PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease.

Teixeira SC, Koolen BB, Elkhuizen PH, Vrancken Peeters MT, Stokkel MP, Rodenhuis S, van der Noort V, Rutgers EJ, Valdés Olmos RA.

Eur J Surg Oncol. 2017 Apr;43(4):625-635. doi: 10.1016/j.ejso.2016.10.012. Epub 2016 Oct 31.

PMID:
27847287
28.

Contribution of SPECT/CT for sentinel node localization in patients with ipsilateral breast cancer relapse.

Borrelli P, Donswijk ML, Stokkel MP, Teixeira SC, van Tinteren H, Rutgers EJ, Valdés Olmos RA.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):630-637. doi: 10.1007/s00259-016-3545-8. Epub 2016 Oct 27.

29.

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

Groen EJ, Elshof LE, Visser LL, Rutgers EJT, Winter-Warnars HAO, Lips EH, Wesseling J.

Breast. 2017 Feb;31:274-283. doi: 10.1016/j.breast.2016.09.001. Epub 2016 Sep 23. Review.

30.

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J.

Breast Cancer Res Treat. 2016 Oct;159(3):553-63. doi: 10.1007/s10549-016-3973-y. Epub 2016 Sep 8. Erratum in: Breast Cancer Res Treat. 2017 Jan;161(2):389-390.

31.

Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.

van der Leij F, van Werkhoven E, Bosma S, Linn SC, Rutgers EJ, van de Vijver MJ, Bartelink H, Elkhuizen PHM, Scholten A.

Breast. 2016 Dec;30:19-25. doi: 10.1016/j.breast.2016.08.004. Epub 2016 Aug 29.

PMID:
27587341
32.

Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study.

Kuijer A, Schreuder K, Elias SG, Smorenburg CH, Rutgers EJ, Siesling S, van Dalen T.

Public Health Genomics. 2016;19(5):276-81. doi: 10.1159/000448278. Epub 2016 Aug 11.

PMID:
27508402
33.

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.

Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F, Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M, Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Försti A, Fostira F, Foulkes WD, Friebel T, Friedman E, Frost D, Gabrielson M, Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Gunter M, Haeberle L, Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S, Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL, Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo P, Peto J, Phelan CM, Pilarski R, Poppe B, Pylkäs K, Radice P, Rahman N, Rantala J, Rappaport C, Rennert G, Richardson A, Robson M, Romieu I, Rudolph A, Rutgers EJ, Sanchez MJ, Santella RM, Sawyer EJ, Schmidt DF, Schmidt MK, Schmutzler RK, Schumacher F, Scott R, Senter L, Sharma P, Simard J, Singer CF, Sinilnikova OM, Soucy P, Southey M, Steinemann D, Stenmark-Askmalm M, Stoppa-Lyonnet D, Swerdlow A, Szabo CI, Tamimi R, Tapper W, Teixeira MR, Teo SH, Terry MB, Thomassen M, Thompson D, Tihomirova L, Toland AE, Tollenaar RA, Tomlinson I, Truong T, Tsimiklis H, Teulé A, Tumino R, Tung N, Turnbull C, Ursin G, van Deurzen CH, van Rensburg EJ, Varon-Mateeva R, Wang Z, Wang-Gohrke S, Weiderpass E, Weitzel JN, Whittemore A, Wildiers H, Winqvist R, Yang XR, Yannoukakos D, Yao S, Zamora MP, Zheng W, Hall P, Kraft P, Vachon C, Slager S, Chenevix-Trench G, Pharoah PD, Monteiro AA, García-Closas M, Easton DF, Antoniou AC.

Nat Commun. 2016 Apr 27;7:11375. doi: 10.1038/ncomms11375.

34.

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.

van Roozendaal LM, Goorts B, Klinkert M, Keymeulen KBMI, De Vries B, Strobbe LJA, Wauters CAP, van Riet YE, Degreef E, Rutgers EJT, Wesseling J, Smidt ML.

Breast Cancer Res Treat. 2016 Apr;156(3):517-525. doi: 10.1007/s10549-016-3783-2. Epub 2016 Apr 15.

35.

[Ductal carcinoma in situ: the balance between over- and undertreatment].

Groen EJ, Elshof LE, Rutgers EJ, Winter-Warnars HA, Lips EH, Wesseling J.

Ned Tijdschr Geneeskd. 2016;160:A9773. Review. Dutch.

PMID:
27071361
36.

Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT.

Teixeira SC, Rebolleda JF, Koolen BB, Wesseling J, Jurado RS, Stokkel MP, Del Puig Cózar Santiago M, van der Noort V, Rutgers EJ, Valdés Olmos RA.

AJR Am J Roentgenol. 2016 Jun;206(6):1307-14. doi: 10.2214/AJR.15.15371. Epub 2016 Apr 8.

PMID:
27058014
37.

Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.

Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, Schinagl DA, Rietveld DH, Versteegh MI, Visser O, Rutgers EJ, Aleman BM, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1061-72. doi: 10.1016/j.ijrobp.2015.11.040. Epub 2015 Dec 14.

PMID:
27026313
38.

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.

Bosma SC, van der Leij F, van Werkhoven E, Bartelink H, Wesseling J, Linn S, Rutgers EJ, van de Vijver MJ, Elkhuizen PH.

Breast Cancer Res Treat. 2016 Apr;156(2):391-400. doi: 10.1007/s10549-016-3732-0. Epub 2016 Mar 23.

PMID:
27008183
39.

Immediate breast reconstruction with a myocutaneous latissimus dorsi flap and implant following skin-sparing salvage mastectomy after irradiation as part of breast-conserving therapy.

van Huizum MA, Hage JJ, Rutgers EJ, Hoornweg MJ.

J Plast Reconstr Aesthet Surg. 2016 Aug;69(8):1080-6. doi: 10.1016/j.bjps.2016.01.018. Epub 2016 Feb 11.

PMID:
26975786
40.

The hidden sentinel node in breast cancer: Reevaluating the role of SPECT/CT and tracer reinjection.

Pouw B, Hellingman D, Kieft M, Vogel WV, van Os KJ, Rutgers EJ, Valdés Olmos RA, Stokkel MP.

Eur J Surg Oncol. 2016 Apr;42(4):497-503. doi: 10.1016/j.ejso.2015.12.009. Epub 2016 Jan 13.

PMID:
26847531
41.

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.

Viale G, Slaets L, de Snoo FA, Bogaerts J, Russo L, van't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Dell'Orto P, Glas AM, Cardoso F.

Breast Cancer Res Treat. 2016 Feb;155(3):463-9. doi: 10.1007/s10549-016-3690-6. Epub 2016 Jan 28.

42.

[The value of ipsilateral breast tumor recurrence as a quality indicator: hospital variation in the Netherlands].

van der Heiden-van der Loo M, Siesling S, Wouters MW, van Dalen T, Rutgers EJ, Peeters PH.

Ned Tijdschr Geneeskd. 2016;160:A9572. Dutch.

PMID:
26813014
43.

[Radiotherapy and breast conserving therapy: past, present and future].

Scholten AN, Rutgers EJ, Bartelink HG.

Ned Tijdschr Geneeskd. 2015;159:A9289. Review. Dutch.

PMID:
26761640
44.

Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.

Teixeira SC, Koolen BB, Vogel WV, Wesseling J, Stokkel MP, Vrancken Peeters MJ, van der Noort V, Rutgers EJ, Valdés Olmos RA.

Clin Nucl Med. 2016 Apr;41(4):e181-6. doi: 10.1097/RLU.0000000000001101.

PMID:
26704731
45.

Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.

van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK.

J Clin Oncol. 2016 Feb 10;34(5):409-18. doi: 10.1200/JCO.2015.62.3942. Epub 2015 Dec 23.

PMID:
26700119
46.

Intraoperative 3D Navigation for Single or Multiple 125I-Seed Localization in Breast-Preserving Cancer Surgery.

Pouw B, de Wit-van der Veen LJ, van Duijnhoven F, Rutgers EJ, Stokkel MP, Valdés Olmos RA, Vrancken Peeters MJ.

Clin Nucl Med. 2016 May;41(5):e216-20. doi: 10.1097/RLU.0000000000001081.

PMID:
26595340
47.

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.

Kuijer A, van Bommel AC, Drukker CA, van der Heiden-van der Loo M, Smorenburg CH, Westenend PJ, Linn SC, Rutgers EJ, Elias SG, van Dalen T.

Genet Med. 2016 Jul;18(7):720-6. doi: 10.1038/gim.2015.152. Epub 2015 Nov 19.

PMID:
26583684
48.

Radioactive seed localization in breast cancer treatment.

Janssen NN, Nijkamp J, Alderliesten T, Loo CE, Rutgers EJ, Sonke JJ, Vrancken Peeters MT.

Br J Surg. 2016 Jan;103(1):70-80. doi: 10.1002/bjs.9962. Epub 2015 Oct 27.

PMID:
26503897
49.

[Axillary lymph node dissection versus axillary radiotherapy in patients with a positive sentinel node: the AMAROS trial].

Donker M, Slaets L, van Tienhoven G, Rutgers EJ.

Ned Tijdschr Geneeskd. 2015;159:A9302. Dutch.

PMID:
26488192
50.

Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer.

Vugts G, Maaskant-Braat AJ, Voogd AC, van Riet YE, Luiten EJ, Rutgers EJ, Rutten HJ, Roumen RM, Nieuwenhuijzen GA.

Breast Cancer Res Treat. 2015 Oct;153(3):549-56. doi: 10.1007/s10549-015-3571-4. Epub 2015 Sep 10.

PMID:
26358709

Supplemental Content

Loading ...
Support Center